A detailed history of Ra Capital Management, L.P. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 9,165,652 shares of JANX stock, worth $520 Million. This represents 5.81% of its overall portfolio holdings.

Number of Shares
9,165,652
Previous 9,165,652 -0.0%
Holding current value
$520 Million
Previous $384 Million 8.45%
% of portfolio
5.81%
Previous 5.79%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $322 Million - $594 Million
9,165,652 New
9,165,652 $384 Million
Q4 2023

Feb 14, 2024

BUY
$5.85 - $11.7 $53.6 Million - $107 Million
9,165,652 New
9,165,652 $98.3 Million
Q3 2023

Nov 14, 2023

BUY
$9.56 - $14.0 $4.73 Million - $6.93 Million
495,008 Added 5.71%
9,165,652 $92.4 Million
Q2 2021

Aug 16, 2021

BUY
$18.58 - $25.37 $161 Million - $220 Million
8,670,644 New
8,670,644 $216 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.36B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Ra Capital Management, L.P. Portfolio

Follow Ra Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ra Capital Management, L.P. with notifications on news.